Swedish pharmaceutical company Orexo AB (STO:ORX) (OTCQX:ORXOY) on Tuesday announced a collaboration with Abera Bioscience to develop nasal powder vaccines using Orexo's AmorphOX technology.
AmorphOX has the potential to improve the stability and efficacy of Abera's vaccine candidates, particularly for intranasal delivery.
The partnership aims to develop powder-based intranasal influenza vaccine candidates, leveraging Abera's innovative vaccine platform and Orexo's drug delivery technology.
The collaboration is funded by Abera through various grants, primarily from the Coalition for Epidemic Preparedness Innovation (CEPI).
Sanofi increases Sanofi Ventures funding by USD625m to boost biotech and digital health investments
GC Biopharma submits IND application in South Korea for Phase 1 trial of COVID-19 vaccine candidate
AusperBio completes patient enrolment in two Phase II clinical trials of AHB-137
LakeShore Biopharma receives Nasdaq delisting determination letter
Valneva reports strong Phase 2 booster results for Lyme disease vaccine candidate VLA15
GC Biopharma files IND for Phase 3 trial of BARYCELA in Thailand
Novavax COVID-19 vaccine approved in US
WHO and UNICEF deploy PharmaJet's Tropis ID system in Afghanistan polio campaign
FDA grants priority review for GSK's gepotidacin gonorrhoea indication
GSK to receive USD370m and future royalties in CureVac/BioNTech settlement
FDA lifts pause on Valneva's chikungunya vaccine IXCHIQ for elderly, updates prescribing information
Anixa Biosciences begins US FDA approved IND transfer to support Phase 2 breast cancer vaccine trial